Wegovy helps improve symptoms of heart failure in people with preserved ejection fraction, according to research in the New England Journal of Medicine.
A new study has highlighted that Wegovy shows broader health benefits than weight loss alone, including improving physical activity and reducing the risk of heart complications.
During the trial, the researchers assigned 529 people who had heart failure with preserved ejection fraction and a body-mass index of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
The results state: “The mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score was 16.6 points with semaglutide and 8.7 points with placebo, and the mean percentage change in body weight was −13.3 per cent with semaglutide and −2.6 per cent with placebo.
“The mean change in the six-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo.”
The findings added: “In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95 per cent CI, 1.37 to 2.15; P<0.001).
“The mean percentage change in the CRP level was –43.5 per cent with semaglutide and –7.3 per cent with placebo (estimated treatment ratio, 0.61; 95 per cent CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3 per cent) in the semaglutide group and 71 (26.7 per cent) in the placebo group.”
To read the full study, click here.
Photo by Siora Photography on Unsplash
